Molecular Detection of CF Lung Pathogens: Current Status and Future Potential

Overview

Journal J Cyst Fibros

Publisher Elsevier

Specialty Pulmonary Medicine

Date 2013 Feb 14

PMID 23402821

Citations 15

Authors

Sally H Pattison

Geraint B Rogers

Martin Crockard

J Stuart Elborn

Michael M Tunney

Affiliations

Soon will be listed here.

Abstract

Molecular diagnostic tests, based on the detection and identification of nucleic acids in human biological samples, are increasingly employed in the diagnosis of infectious diseases and may be of future benefit to CF microbiology services. Our growing understanding of the complex polymicrobial nature of CF airway infection has highlighted current and likely future shortcomings in standard diagnostic practices. Failure to detect fastidious or slow growing microbes and misidentification of newly emerging pathogens could potentially be addressed using culture-independent molecular technologies with high target specificity. This review considers existing molecular diagnostic tests in the context of the key requirements for an envisaged CF microbiology focussed assay. The issues of assay speed, throughput, detection of multiple pathogens, data interpretation and antimicrobial susceptibility testing are discussed.

Citing Articles

Bacterial Culture Underestimates Lung Pathogen Detection and Infection Status in Cystic Fibrosis.

Gavillet H, Hatfield L, Rivett D, Jones A, Maitra A, Horsley A Microbiol Spectr. 2022; 10(5):e0041922.

PMID: 35972283 PMC: 9602735. DOI: 10.1128/spectrum.00419-22.

Genomic diversity and antimicrobial resistance of species isolated from chronic lung disease airways.

Webb K, Olagoke O, Baird T, Neill J, Pham A, Wells T Microb Genom. 2022; 8(2).

PMID: 35113778 PMC: 8942031. DOI: 10.1099/mgen.0.000754.

Lung function and microbiota diversity in cystic fibrosis.

Cuthbertson L, Walker A, Oliver A, Rogers G, Rivett D, Hampton T Microbiome. 2020; 8(1):45.

PMID: 32238195 PMC: 7114784. DOI: 10.1186/s40168-020-00810-3.

Cooperativity between Stenotrophomonas maltophilia and Pseudomonas aeruginosa during Polymicrobial Airway Infections.

McDaniel M, Schoeb T, Swords W Infect Immun. 2020; 88(4).

PMID: 31932329 PMC: 7093137. DOI: 10.1128/IAI.00855-19.

Detection of viable but non-culturable Pseudomonas aeruginosa in cystic fibrosis by qPCR: a validation study.

Mangiaterra G, Amiri M, Di Cesare A, Pasquaroli S, Manso E, Cirilli N BMC Infect Dis. 2018; 18(1):701.

PMID: 30587160 PMC: 6307279. DOI: 10.1186/s12879-018-3612-9.

References

Stressmann F, Rogers G, van der Gast C, Marsh P, Vermeer L, Carroll M . Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax. 2012; 67(10):867-73. DOI: 10.1136/thoraxjnl-2011-200932. View

Ghegan M, Wise S, White D, Flume P, Bowman C, Virella-Lowell I . Cost-effective airway cultures in the cystic fibrosis patient. Am J Otolaryngol. 2009; 30(3):150-2. DOI: 10.1016/j.amjoto.2008.03.006. View

Worlitzsch D, Rintelen C, Bohm K, Wollschlager B, Merkel N, Borneff-Lipp M . Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect. 2009; 15(5):454-60. DOI: 10.1111/j.1469-0691.2008.02659.x. View

Gaillot O, Blondiaux N, Loiez C, Wallet F, Lemaitre N, Herwegh S . Cost-effectiveness of switch to matrix-assisted laser desorption ionization-time of flight mass spectrometry for routine bacterial identification. J Clin Microbiol. 2011; 49(12):4412. PMC: 3232935. DOI: 10.1128/JCM.05429-11. View

Kirchner S, Fothergill J, Wright E, James C, Mowat E, Winstanley C . Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung. J Vis Exp. 2012; (64):e3857. PMC: 3471314. DOI: 10.3791/3857. View

Bittar F, Richet H, Dubus J, Reynaud-Gaubert M, Stremler N, Sarles J . Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One. 2008; 3(8):e2908. PMC: 2483419. DOI: 10.1371/journal.pone.0002908. View

Waldeisen J, Wang T, Mitra D, Lee L . A real-time PCR antibiogram for drug-resistant sepsis. PLoS One. 2011; 6(12):e28528. PMC: 3229610. DOI: 10.1371/journal.pone.0028528. View

Harkins A, Munson E . Molecular Diagnosis of Sexually Transmitted Chlamydia trachomatis in the United States. ISRN Obstet Gynecol. 2011; 2011:279149. PMC: 3148448. DOI: 10.5402/2011/279149. View

Moskowitz S, Foster J, Emerson J, Burns J . Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004; 42(5):1915-22. PMC: 404629. DOI: 10.1128/JCM.42.5.1915-1922.2004. View

10.

Mayer-Hamblett N, Kronmal R, Gibson R, Rosenfeld M, Retsch-Bogart G, Treggiari M . Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol. 2011; 47(2):125-34. PMC: 3214247. DOI: 10.1002/ppul.21525. View

11.

Compton J . Nucleic acid sequence-based amplification. Nature. 1991; 350(6313):91-2. DOI: 10.1038/350091a0. View

12.

Zemanick E, Wagner B, Harris J, Wagener J, Accurso F, Sagel S . Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures. Pediatr Pulmonol. 2010; 45(6):569-77. PMC: 2937349. DOI: 10.1002/ppul.21221. View

13.

Vanlaere E, Sergeant K, Dawyndt P, Kallow W, Erhard M, Sutton H . Matrix-assisted laser desorption ionisation-time-of of-flight mass spectrometry of intact cells allows rapid identification of Burkholderia cepacia complex. J Microbiol Methods. 2008; 75(2):279-86. DOI: 10.1016/j.mimet.2008.06.016. View

14.

Harris J, De Groote M, Sagel S, Zemanick E, Kapsner R, Penvari C . Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A. 2007; 104(51):20529-33. PMC: 2154465. DOI: 10.1073/pnas.0709804104. View

15.

Lang B, Aaron S, Ferris W, Hebert P, MacDonald N . Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2000; 162(6):2241-5. DOI: 10.1164/ajrccm.162.6.2005018. View

16.

Daniels T, Rogers G, Stressmann F, van der Gast C, Bruce K, Jones G . Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. J Cyst Fibros. 2012; 12(1):22-8. DOI: 10.1016/j.jcf.2012.05.008. View

17.

Shreve M, Butler S, Kaplowitz H, Rabin H, Stokes D, Light M . Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol. 1999; 37(3):753-7. PMC: 84543. DOI: 10.1128/JCM.37.3.753-757.1999. View

18.

Rolain J, Mallet M, Fournier P, Raoult D . Real-time PCR for universal antibiotic susceptibility testing. J Antimicrob Chemother. 2004; 54(2):538-41. DOI: 10.1093/jac/dkh324. View

19.

Weigel L, Sue D, Michel P, Kitchel B, Pillai S . A rapid antimicrobial susceptibility test for Bacillus anthracis. Antimicrob Agents Chemother. 2010; 54(7):2793-800. PMC: 2897299. DOI: 10.1128/AAC.00247-10. View

20.

Tunney M, Klem E, Fodor A, Gilpin D, Moriarty T, McGrath S . Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax. 2011; 66(7):579-84. DOI: 10.1136/thx.2010.137281. View